Author: Rajan, Anubama; Weaver, Ashley Morgan; Aloisio, Gina Marie; Jelinski, Joseph; Johnson, Hannah L.; Venable, Susan F.; McBride, Trevor; Aideyan, Letisha; Piedra, Felipe-Andrés; Ye, Xunyan; Melicoff-Portillo, Ernestina; Yerramilli, Malli Rama Kanthi; Zeng, Xi-Lei; Mancini, Michael A; Stossi, Fabio; Maresso, Anthony W.; Kotkar, Shalaka A.; Estes, Mary K.; Blutt, Sarah; Avadhanula, Vasanthi; Piedra, Pedro A.
Title: The human nose organoid respiratory virus model: an ex-vivo human challenge model to study RSV and SARS-CoV-2 pathogenesis and evaluate therapeutics Cord-id: sqtk8dpm Document date: 2021_7_28
ID: sqtk8dpm
Snippet: There is an unmet need for pre-clinical models to understand the pathogenesis of human respiratory viruses; and predict responsiveness to immunotherapies. Airway organoids can serve as an ex-vivo human airway model to study respiratory viral pathogenesis; however, they rely on invasive techniques to obtain patient samples. Here, we report a non-invasive technique to generate human nose organoids (HNOs) as an alternate to biopsy derived organoids. We made air liquid interface (ALI) cultures from
Document: There is an unmet need for pre-clinical models to understand the pathogenesis of human respiratory viruses; and predict responsiveness to immunotherapies. Airway organoids can serve as an ex-vivo human airway model to study respiratory viral pathogenesis; however, they rely on invasive techniques to obtain patient samples. Here, we report a non-invasive technique to generate human nose organoids (HNOs) as an alternate to biopsy derived organoids. We made air liquid interface (ALI) cultures from HNOs and assessed infection with two major human respiratory viruses, respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Infected HNO-ALI cultures recapitulate aspects of RSV and SARS-CoV-2 infection, including viral shedding, ciliary damage, innate immune responses, and mucus hyper-secretion. Next, we evaluated the feasibility of the HNO-ALI respiratory virus model system to test the efficacy of palivizumab to prevent RSV infection. Palivizumab was administered in the basolateral compartment (circulation) while viral infection occurred in the apical ciliated cells (airways), simulating the events in infants. In our model, palivizumab effectively prevented RSV infection in a concentration dependent manner. Thus, the HNO-ALI model can serve as an alternate to lung organoids to study respiratory viruses and testing therapeutics.
Search related documents:
Co phrase search for related documents- activation regulate and lung tissue: 1
- acute respiratory syndrome and administration dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and long term study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and low amount: 1, 2, 3, 4
- acute respiratory syndrome and low compartment: 1, 2, 3
- acute respiratory syndrome and lung biopsy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- administration dose and long term study: 1, 2
- administration dose and lung biopsy: 1
- administration dose and lung tissue: 1, 2, 3, 4, 5
- long term study and lung tissue: 1, 2
- low amount and lung tissue: 1
- low compartment and lung tissue: 1
Co phrase search for related documents, hyperlinks ordered by date